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CC BY-NC-ND license (http://creativeAbstract Hepatocellular carcinoma (HCC) is a primary malignancy of the liver. Patients with
HCC usually have poor prognosis and high mortality. It has been shown that carcinoembryonic
antigen-related cell adhesion molecule 1 (CD66a) regulates cell signaling, proliferation, and
tumor growth. The aim of this study is to analyze the expression and possible role of CD66a
in HCC. Immunohistochemical staining of CD66a was performed on 86 HCC cases, and microves-
sel density was evaluated by CD34 immunostaining. The results were further correlated with
clinicopathological parameters. For 47 of 86 HCC cases, the CD66a expression showed diffuse
membrane or cytoplasmic staining. The other 39 HCC cases revealed loss of CD66a expression.
Loss of CD66a expression was statistically significantly associated with large tumor size
(pZ 0.016), fatty change (pZ 0.039), patients with transcatheter arterial embolization
(pZ 0.007), and high microvessel density (pZ 0.036). CD34 expression had no significant as-
sociation with tumor size, virus infection, histological grade, and capsular invasion. The diffuse
and cytoplasmic expression of CD66a may involve the early stage of the HCC, and the loss of
CD66a expression indicates tumor progression.
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Hepatocellular carcinoma (HCC) is one of the most common
malignant tumors worldwide [1]. Chronic infections of hep-
atitis B virus (HBV) and hepatitis C virus are associated with
HCC, although themechanismof the hepatocarcinogenesis is
unclear. It has been shown that more than one-half of adult
HCC patients worldwide are related to HBV infection [2].
Previous studies also showed that not only chronic inflam-
mation and the effects of cytokines are major factors for the
development of HCC [3], but an integration of HBV-DNA into
the host cellular genome is also considered an important
factor to enhance genomic instability and trigger specific
oncogenic pathways [4]. HBVmutations in core promoter and
precore regions have been reported to be linked to the
severity of liver diseases and development of HCC [5]. In
addition, different HBV genotypes have been found to be
associated with different mutation rates of HBV and
contribute to hepatocarcinogenesis [6].
Carcinoembryonic antigen-related cell adhesion mole-
cule 1 (CD66a), so-called biliary glycoprotein, is a member
of the carcinoembryonic antigen subfamily and belongs to
the immunoglobulin superfamily. Therefore, CD66a consists
of both structural features of the immunoglobulin super-
family and functional properties of the cadherin family of
cell adhesion molecules [7,8]. It has been reported that
CD66a regulates various cellular functions, including cell
signaling, proliferation [9], apoptosis [10], angiogenesis
[11], tumor growth [12], and epithelial cell polarization
[10]. It has been demonstrated that CD66a expression in
lung carcinoma [13] and malignant melanoma [14] is
considered as a significant prognostic factor. By contrast, a
loss or decrease of CD66a expression was found in various
kinds of malignancies, including those of the breast [15],
endometrium [16], colon [17], and liver [18]. However, the
prognostic significance of CD66a in HCC is still unknown. In
normal hepatocytes and low-grade HCC, the CD66a
expression shows diffuse immunostaining, but most high-
grade liver tumors reveal a loss or decrease of CD66a
expression [18,19]. The aim of our study was to find out
whether the expression of CD66a in HCC is associated with
the prognosis, and to investigate the relationship between
CD66a expression and angiogenesis in HCC.
Materials and methods
Patients
Eighty-six consecutive patients underwent curative partial
hepatectomy as an initial treatment for HCC at the
Department of Hepatobiliary in Kaohsiung Medical Univer-
sity Hospital (Kaohsiung, Taiwan) during the 10-year study
period. Each specimen was examined, and clinicopatho-
logical parameters including age, sex, virus infection,
alpha-fetoprotein, histological grade, vascular invasion,
capsular invasion, inflammation, fibrosis, cirrhosis, and
fatty change status of the adjacent liver were recorded.
Clinical histories of the cases were obtained from their
medical records. This study was performed after obtaining
approval from the Kaohsiung Medical University Hospital
Institutional Review Board (KMUH-IRB-20120054).Tissue microarray preparation
Hematoxylineeosin slides were examined under a light mi-
croscope. The representative regions were marked. A
handmadepapermoldwith 40 (8 5) holeswas preparedand
taped on an open box previously. A 16-gauge bone marrow
aspiration needle was used to punch paraffin wax cylinders
(2mm in diameter). The tissue corewas carefully transferred
using forceps to the prepared paper mold. After all the cyl-
inders were implanted in the mold, the mold was embedded
with paraffin. Prior to sectioning, the tissue array paraffin
block was removed from the mold and cooled to 10C.
Sections (4 mm thick) were cut using an ordinary microtome.
Immunohistochemical staining
One to four paraffin-embedded block(s) (median, 2 blocks)
from each resected specimen were used for immunohisto-
chemical (IHC) staining. Four serial sections, 4 mm thick,
were cut from each microarray block: one for routine his-
tologic examination using hematoxylineeosin staining, two
for IHC staining, and one for a negative control. Two in-
dependent surgical pathologists blinded to clinical details
assessed each section.
A mouse monoclonal antibody against NCL-CD66a (VP-
C363; Vector Laboratories Inc., Burlingame, CA, USA) and
CD34 (M7165; Dako, Carpinteria, CA, USA), was used at a
dilution of 1:50. The streptavidinebiotin immunoperox-
idase method was used. The sections were deparaffinized
and rehydrated, and then microwaved at 500 W for seven
cycles of 3 minutes in 10 mmol/L citrate buffer (pH 6.0) to
retrieve antigen activity. After blocking of endogenous
peroxidase, sections were incubated overnight at 4C with
anti-CD66a or CD34 antibody. They were then incubated
at room temperature for 30 minutes with goat antimouse
immunoglobulin conjugated to a peroxidase-labeled
amino acid polymer, Simple Stain Max PO (M) (Nichirei,
Tokyo, Japan). Diaminobenzidine was used as the chro-
mogen, and the sections were counterstained with he-
matoxylin. Negative internal controls were treated the
same way except for incubation with the primary anti-
body. Adjacent non-neoplastic liver tissue was used as a
positive control.
Microvessel density (MVD) was defined as the number of
CD34-positive staining vessels per field counted in the area
of highest vascular density, as described previously [20].
Individual stained microvessels were counted at 400 mag-
nifications. Random five fields, which appeared to contain
the greatest number of microvessels in the areas per tumor
section, were counted. The average of counts in these
fields was considered in the analysis. All numbers in the
text are quoted per mm2.
Statistical analysis
CD66a expression was analyzed with clinicopathological
parameters using chi-square test, and for survival time by
the KaplaneMeier method. CD34 expression was analyzed
using independent t test. Statistical significance was
considered when p< 0.05. All statistical analyses were
performed using SPSS19 (SPSS, Chicago, IL, USA).
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Pattern of CD66a expression in hepatocytes and
HCC
Nontumorous hepatocytes showed strong CD66a expression
in the canalicular membrane (Figure 1A). For HCC, the
CD66a expression was classified into three categories:
diffuse expression, characterized by positive staining
throughout the tumor specimen (Figure 1B); luminal
expression, characterized by positive staining within the
lumen-like structures in tumor cells (Figure 1C); and loss ofFigure 1. CD66a expression pattern in hepatocytes and HCC. CD6
diffusely cytoplasmic staining, (C) luminal staining, and (D) loss of
associated with CD66a expression (mean SE). HCCZ hepatocell
significant.expression (39 cases), in which there were distinct areas of
negative staining within the tumor specimen (Figure 1D).
Chi-square analysis showed that CD66a expression was not
significantly correlated with age, sex, virus infection,
serum alpha-fetoprotein level, stage, recurrence, histo-
logical grade, vascular invasion, capsular invasion, inflam-
mation, fibrosis, and cirrhosis. CD66a was significantly
associated with transcatheter arterial embolization and
fatty change (Table 1). The mean tumor size of HCC with
CD66a expression (47 cases) was 3.70 2.13 cm, and the
mean tumor size of the other 39 HCC cases without CD66a
expression was 5.81 4.95 cm. Independent t test also6a showed (A) canalicular pattern in normal liver tissue, and (B)
CD66a expression in HCC. (E) Tumor size in HCC is significantly
ular carcinoma; SEZ standard error. ) p < 0.05, statistically
Table 1 Relationship between CD66a expression and
clinicopathological parameters.
CD66a expression, n (%) p
1 2 3
Age (y) 0.502
<50 3 (15.0) 8 (40.0) 9 (45.0)
50 16 (22.6) 18 (28.1) 30 (46.9)
Sex 0.274
Female 3 (17.6) 8 (47.1) 6 (35.3)
Male 16 (23.9) 18 (35.3) 33 (49.3)
Virus 0.305
None 1 (14.3) 4 (57.1) 2 (28.6)
HBV 13 (28.3) 13 (28.3) 20 (43.5)
HCV 2 (9.1) 6 (27.3) 14 (63.6)
HBVþ HCV 3 (33.3) 3 (33.3) 3 (33.3)
Serum AFP (ng/dL) 0.429
20 4 (12.9) 12 (38.7) 15 (48.4)
>20 10 (22.7) 12 (27.3) 22 (50.0)
Unknown 5 2 2
Stage 0.638
I/II 16 (21.0) 17 (33.9) 29 (45.2)
III/IV 3 (9.1) 9 (40.9) 10 (50.0)
Recurrence 0.066
Absent 9 (18.4) 12 (24.5) 28 (57.1)
Present 10 (28.6) 14 (40.0) 11 (41.7)
TAE 0.007*
Absent 14 (23.9) 17 (43.5) 14 (31.1)
Present 5 (13.2) 9 (26.3) 24 (64.9)
Unknown 1
Histologic grade 0.733
Grade 1 2 (14.3) 5 (35.7) 7 (50.0)
Grade 2 14 (24.1) 19 (32.8) 25 (43.3)
Grade 3 3 (25.0) 2 (16.7) 7 (58.3)
Vascular invasion 0.748
Absent 13 (22.8) 19 (33.3) 25 (43.9)
Present 6 (22.2) 7 (25.9) 14 (51.9)
Capsular invasion 0.436
Absent 16 (26.2) 18 (29.5) 27 (44.3)
Present 3 (13.0) 8 (34.8) 12 (52.2)
Inflammation 0.711
Grade 1 1 (33.3) 1 (33.3) 1 (33.3)
Grade 2 0 (0) 2 (33.3) 4 (66.7)
Grade 3 2 (40.0) 2 (40.0) 1 (20.0)
Grade 4 16 (20.8) 21 (30.0) 33 (47.1)
Fibrosis 0.568
Stage 1 0 (0) 0 (0) 1 (100.0)
Stage 2 2 (9.5) 8 (38.1) 11 (52.4)
Stage 3 6 (27.3) 5 (22.7) 11 (50.0)
Stage 4 11 (27.5) 13 (32.5) 16 (40.0)
Cirrhosis 0.462
Absent 8 (18.2) 13 (29.5) 23 (52.3)
Present 11 (27.5) 13 (32.5) 16 (40.0)
Fatty change 0.039*
5% 5 (16.1) 7 (22.6) 19 (61.3)
>5%e33% 11 (28.2) 13 (33.3) 15 (38.5)
>33%e66% 1 (8.3) 6 (50.0) 5 (41.7)
>66% 2 (100.0) 0 (0) 0 (0)
Table 1 (continued )
CD66a expression, n (%) p
1 2 3
MVD 0.036*
Low density 9 (18.0) 12 (24.0) 29 (58.0)
High density 10 (29.4) 14 (41.2) 10 (29.4)
* p< 0.05, statistically significant.
AFPZ alpha-fetoprotein; HBVZ hepatitis B virus; HCVZ he-
patitis C virus; MVDZmicrovessel density; TAEZ transcatheter
arterial embolization.
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with tumor size (pZ 0.016; Figure 1E). However, the
KaplaneMeier method showed that CD66a expression was
not associated with survival time (data not shown).
Pattern of CD34 expression in HCC
CD34 immunostaining highlights the endothelial cells within
HCC (Figure 2). We used the MVD to assess the total
numbers of microvessels. Independent t test showed that
CD34 expression had no significant association with tumor
size, virus infection, histological grade, and capsular inva-
sion. CD34 was associated with clinical stage and vascular
invasion (Table 2).
Correlation between CD66a and MVD
The mean intratumor MVD of the total HCC cases was
82.23 27.1 (range: 24.33e158.67). MVD was considered
low when its value was 82.23 and high when the value was
>82.23. Chi-square analysis was used to analyze the asso-
ciation between CD66a and MVD. The result showed that
high MVD had loss of CD66a expression. By contrast, HCC
with positive staining of CD66a usually showed low MVD.
CD66a expression was significantly associated with MVD
(pZ 0.036; Table 1).
Discussion
CD66a is considered a tumor suppressor in various malig-
nancies, including breast cancer [21] and prostate cancer
[22]. However, upregulated CD66a expression is likely to be
an adverse prognostic factor in lung carcinoma and malig-
nant melanoma [14,23]. A previous study reported that loss
of expression of CD66a is an independent factor for poor
prognosis in HCC patients [24]. In our study, the expression
of CD66a was significantly associated with post-
transcatheter arterial embolization treatment, but not
with histological grade or clinical stage. When embolization
was performed before the surgical procedure, a wide range
of tumor necrosis was present in the specimen. In this sit-
uation, tissue sampling for sectioning included necrotic
area and its adjacent residual tumor tissue. We found that
the cancer cells farther away from the tumor center were
Figure 2. CD34 expression in HCC. CD34 immunostaining in HCC revealed (A) low MVD in low-grade HCC and (B) high MVD in high-
grade HCC. HCCZ hepatocellular carcinoma; MVDZmicrovessel density.
Table 2 Relationship between MVD and clinicopatholog-
ical parameters.
Parameters MVD, mean SD p
Tumor size (cm)
<5 87.98  26.65
5 79.15  23.88 0.176
Virus infection
None 79.91  18.16
HBV 82.74  24.55 0.774
HCV 85.96  27.78 0.597
HBVþ HCV 98.83  33.21 0.219
Clinical stage
I/II 91.38  25.67
III/IV 68.84  18.82 0.001*
Histological grade
Grade 1 94.23  28.62
Grade 2 94.23  24.66 0.230
Grade 3 70.88  22.87 0.066
Vascular invasion
Absent 90.34  26.77
Present 73.68  19.38 0.010*
Capsular invasion
Absent 83.98  23.85
Present 86.77  30.23 0.685
Fatty change
<5% 77.26  25.44
5e33% 85.65  24.67 0.213
33e66% 98.55  25.19 0.028*
>66%
* p< 0.05, statistically significant.
HBVZ hepatitis B virus; HCVZ hepatitis C virus; MVDZmi-
crovessel density; SDZ standard deviation.
310 C.-C. Wu et al.able to survive and were less affected by embolization. In
addition, cancer cells with high-grade histologic features
were more resistant to hypoxia caused by embolization and
survived.
It has been shown that tumor size after embolization
treatment is significantly related to distant metastasis [25].
It indicates that residual cancer cells within a larger tumor
that survive after embolization treatment are likely to
cause distant metastasis. Our results also showed that the
residual cancer cells were found to be absence of CD66a
expression after embolization treatment. In addition,CD66a expression was significantly associated with tumor
size. In fact, a larger tumor size will cause more hypoxic
environment areas in the tumors. Cancer cells with higher
histological grade and aggressive biological behavior usually
tolerate and survive in the hypoxic environment. There-
fore, it is consistent with our result that revealed loss of
CD66a staining in larger HCC tumors.
In our study, CD66a expression was also associated with
fatty change. The function of CD66a is to adjust the insulin
clearance in the liver so that the insulin concentration in
the blood is increased. Once the blood continues to main-
tain a high concentration of insulin, tissue insulin resistance
and glucose tolerance will result; hence, fat easily accu-
mulates in the organ [26,27]. Therefore, we speculate that
CD66a may be involved in the development of fatty liver
and may play an important role in hepatocarcinogenesis.
Angiogenesis is characterized by proliferation of new
blood vessels from endothelial cells and occurs during
wound repair, reproduction, and development. The angio-
genesis process includes cell migration, proliferation,
microvascular differentiation, extracellular matrix degra-
dation, and structural reorganization [28]. It has been
shown that tumor growth is associated with angiogenesis,
by biological, pharmacological, and genetic evidence [29].
Endothelial progenitor cells from bone marrow are
recruited to the vascular bed of tumors and contribute to
tumor growth [30]. MVD is a reliable indicator for evaluating
angiogenesis in tumors. IHC staining of vascular endothelial
cell markers, such as CD34, CD31, and vascular endothelial
growth factor, is used for highlighting the vascular channels
in a tumor [31e34]. Previous studies have reported that
MVD was an adverse predictor in several cancers [35],
including HCC [33] and pancreatic cancer [36]. In our study,
MVD was significantly compared with clinical stage,
vascular invasion, and fatty change.
Loss of CD66a expression may predict poor survival after
resection because it represents aggressive tumor biology
characterized by large tumor size and higher histological
grade. Our results showed that well-differentiated HCCs
(Grades 1 and 2) were characterized by diffuse CD66a
expression. As the tumor progressed, poorly differentiated
foci (Grade 3) revealed loss of CD66a expression and
emerged within the background tumor tissue that
had diffuse CD66a expression [37]. Loss of CD66a expression
in the foci always had a high histological grade, suggesting
that loss of CD66a expression may reflect the
CD66a in hepatocellular carcinoma 311dedifferentiation of HCC cells. CD66a expression is down-
regulated with increasing histological grade in malignant
cells derived from the liver, endometrium, and prostate.
Cervello et al. [38] showed loss of CD66a expression in 80%
of poorly differentiated or undifferentiated HCCs, but not
in well-differentiated tumors. The current study also
revealed a high frequency of loss of CD66a expression in
poorly differentiated HCCs (Grade 3). These findings sug-
gest that loss of CD66a expression is usually a late event in
the progression of HCC.
In colorectal adenocarcinoma, Neumaier et al. [39] re-
ported that reduced CD66a expression of tumor cells was
associated with regional lymph node metastasis. Pu et al.
[40] found that in a transgenic mouse model of prostate
carcinoma, expression of an epithelial cell adhesion mole-
cule (a mouse homolog of CD66a) was lost in tumor cells
involving lymph nodes. These data suggest that loss of
CD66a expression in cells from a variety of tumors indicates
a high metastatic potential. In conclusion, loss of CD66a
expression of tumor cells may reflect the dedifferentiation
of cancer cells in HCC. It also reflects aggressive tumor
biology and thus indicates a poor prognosis for patients with
HCC.
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